Abstract
Staphylococcus aureus bacteremia is common and associated with fatality rates approximating 25%. We provide a brief overview of S. aureus bacteremia from a clinical and microbiological lens and review the relevant evidence and literature gaps in its management. Using a case-based approach, evidence and clinical judgement are meshed to highlight and justify the 5 core interventions that ought to be performed for all cases of S. aureus bacteremia: 1) appropriate anti-staphylococcal therapy, 2) screening echocardiography, 3) assessment for metastatic phenomena and source control, 4) decision on duration of antimicrobial therapy, and 5) Infectious Diseases consultation.
Keywords
Clinical Significance
- •Staphylococcus aureus is responsible for a diverse burden of human diseases.
- •S. aureus bacteremia is common, and has fatality rates approximating 25%.
- •S. aureus’ affinity for foreign material and antimicrobial resistance renders S. aureus bacteremia treatment challenging.
- •In patients with S. aureus bacteremia, the following interventions should be undertaken: 1) appropriate anti-staphylococcal therapy, 2) screening echocardiography, 3) assessment for metastatic phenomena and source control, 4) decision on duration of antimicrobial therapy, 5) Infectious Diseases consultation.
Clinical Cases
Case 1
A 78-year-old woman is hospitalized with hypoxemia. Index blood cultures (BCx) did not isolate a pathogen. A diagnosis of congestive heart failure was made and she improved with diuresis. Four days later she developed swelling and tenderness at her peripheral intravenous line site. BCx yielded methicillin-sensitive Staphylococcus aureus (MSSA) and her intravenous line was removed. There are no other sites of infection and repeat BCx taken 2 days after antibiotic initiation are negative.
Case 2
A 45-year-old man with lumbar degenerative disc disease presents with a 2-day history of low back pain after sustaining a musculoskeletal injury from lifting furniture 1 week ago. Accompanied by fevers and chills, his examination is relevant for L5 vertebral tenderness. BCx are positive for MSSA. Plain radiographs and magnetic resonance imaging (MRI) of his lumbar spine are unremarkable.
Case 3
A 29-year-old woman who injects drugs is hospitalized for left knee pain and methicillin-resistant S. aureus (MRSA) bacteremia. Clinical assessment reveals a tender, swollen joint with limited range of motion. Synovial fluid culture from an irrigation and debridement of her left knee yields MRSA. A transthoracic echocardiogram (TTE) reveals a 0.5 cm × 0.5 cm vegetation on her tricuspid valve with moderate tricuspid regurgitation. Despite 8 days of therapeutic vancomycin, serial BCx remain positive for MRSA. Computed tomography (CT) of her chest, abdomen, and pelvis is unremarkable.
Questions to consider for each patient:
- 1.What other investigations should be considered?
- 2.What is the role of echocardiogram?
- 3.What choice, route, and duration of antibiotic(s) should be administered?
- 4.What is the role of Infectious Diseases (ID) consultation?
Epidemiology and Relevance
S. aureus is a colonizer of mucous membranes, skin, and gastrointestinal tract, carried by up to 80% of the population. Nasal carriage of S. aureus is most common, and increases with health care exposure, diabetes, dialysis, substance drug use, and human immunodeficiency virus infection.
1
While most carriers of S. aureus do not go on to develop illness, colonization often precedes infection.S. aureus bacteremia remains a common cause of bloodstream infection. It has an annual population-based incidence rate upwards of 50 cases/100,000 population and mortality rate approximating 20%-30% in developed countries despite effective antibacterial therapies and source control strategies.
2
In contrast, 30-day mortality from an acute myocardial infarction approximates 10%.3
In the United States, prevalence of MRSA amongst S. aureus clinical isolates is upwards of 50% and significant enough to justify empiric MRSA treatment in S. aureus bacteremia. However, rates continue to decrease with rigorous infection control measure implementations.
4
In comparison, both Canada and Europe have lower MRSA prevalence, although European MRSA prevalence increases substantially with decreasing latitude (eg, <5% in Northern European countries compared with over 25% among Southern Europe).5
European Centre for Disease Prevention and Control (ECDC). Surveillance atlas of infectious diseases. Available at:https://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&HealthTopic=4. Accessed June 19, 2022.
Patients with S. aureus bacteremia have a spectrum of clinical presentations; some are asymptomatic with incidentally identified primary bacteremia, while others have a sustained bloodstream infection complicated by embolic phenomena. The mechanism of disease from S. aureus is not well understood and thought to be mediated by the relationship between host susceptibility and pathogen virulence factors.
Despite the lethality of S. aureus bacteremia, there remain no contemporary uniform guidelines to inform clinical practice. Rather, the evidence that guides the treatment of patients with S. aureus bacteremia focus on specific questions (eg, comparison of antibacterials, comparison of cardiac imaging modalities) rather than S. aureus bacteremia as an entity in itself.
6
,7
Regardless, a series of diagnostic and therapeutic investigations should be performed in all patients with S. aureus bacteremia. These include: 1) appropriate anti-staphylococcal therapy, 2) screening echocardiography, 3) assessment for metastatic phenomena and source control, 4) decision on duration of antimicrobial therapy, and 5) ID consultation (Figure).
FigureProposed flow diagram for Staphylococcus aureus bacteremia management. May differ depending on recommendations by local ID consultants.
Show full caption
Abx = antibiotic; BCx = blood culture; CT = computed tomography; CV = cardiovascular; ID = Infectious Diseases; CXR = chest X-ray study; IE = infective endocarditis; IV = intravenous; MRI = magnetic resonance imaging; MRSA = methicillin-resistant Staphylococcus aureus; MSSA = methicillin-susceptible Staphylococcus aureus; PET-CT = positive emission tomography-computed tomography; TEE = transesophageal echocardiogram; SAB = s.aureus bacteremia; TTE = transthoracic echocardiogram.
Microbiology
S. aureus is a Gram-positive, facultatively anaerobic coccus with unique virulent properties. In brief, S. aureus adhesins allow migration into the bloodstream followed by attachment to biotic and abiotic surfaces. Once attached, S. aureus coagulase interacts with fibrinogen to form hardy, drug-resistant biofilms.
8
Toxins produced by S. aureus can lyse leukocytes and evade host immune systems. Certain S. aureus strains, particularly within community-acquired MRSA, produce Panton-Valentine leukocidin (PVL), a cytolytic toxin associated with granulocyte destruction. The presence of PVL can be associated with severe, deep-seated S. aureus infections in hosts with high inflammatory markers but relative leukopenia.
9
While in vitro data of S. aureus strains with PVL suggests a benefit with usage of adjunctive toxin inhibitory antibiotics such as rifampin, clindamycin, or linezolid, clinical benefit has not been reflective of the same.10
S. aureus is seldom considered nonpathogenic when identified in BCx. Risk factors associated with S. aureus contamination are not well defined. In our experience, pseudobacteremia is more common among patients with papulosquamous skin disease (eg, eczema, psoriasis). If contamination is suspected, close follow-up with clinical monitoring and serial BCx is advised.
Time to BCx positivity may predict speciation, severity, and etiology of staphylococcal bacteremia. For example, 1/4 positive BCx for Gram-positive cocci in clumps after 24 hours are more likely to be coagulase-negative Staphylococci, whereas S. aureus BCx positivity within 14 hours is associated with endovascular infection, persistent bacteremia, and metastatic complications.
11
Time to positivity difference of ≥2 hours between BCx taken from central lines and those taken from peripheral sites are suggestive of central-line-associated bloodstream infection.Bacteremia with MRSA is associated with poorer clinical outcomes compared with MSSA; likely due to increased virulence and drug-resistance. The dysfunction of the accessory gene regulator (agr), a protein that modulates S. aureus virulence factors, is a key contributor to virulence of MRSA. Its dysfunction is associated with prolonged bacteremia via increasing glycopeptide (e.g. vancomycin) resistance through various mechanisms including adhesin overexpression.
12
Antimicrobial resistance to vancomycin in S. aureus can develop in 3 main ways: modifications of S. aureus’ cell wall, “minimal inhibitory concentration (MIC) creep,” and acquisition of vanA plasmids.
Vancomycin (or glycopeptide)-intermediate S. aureus (VISA or GISA) and heterogenous VISA (hVISA) strains are less susceptible to vancomycin due to increasing cell wall thickness. Compared with VISA, the number of S. aureus subpopulations in hVISA have variable ranges of vancomycin susceptibility. In contrast, MIC creep is not a method of resistance per se but represents a phenomenon of increasing vancomycin MICs among S. aureus over time. Compared with an MIC <2 ug/mL, isolates of MRSA with a MIC of 2 ug/mL treated with vancomycin may be associated with unfavorable clinical outcomes and be precursors to VISA and hVISA.
13
However, interpretation of vancomycin “MIC creep” and its clinical relevance remains varied. Both the American and European susceptibility guidelines continue to recommend MRSA isolates with a MIC of 2 ug/mL susceptible to vancomycin, although some centers may report caution with vancomycin use in these cases. Vancomycin MICs between 4 and 8 ug/mL (VISA, hVISA) and MIC ≥16 ug/mL (VRSA) are reported as indeterminate and resistant, respectively. Vancomycin resistance is rare and most commonly mediated by acquisition of vanA plasmids from vancomycin resistant Enterococci. VanA confers resistance by altering the peptide target of glycopeptides.Even less common is resistance to daptomycin, tigecycline, linezolid, and anti-MRSA beta-lactams (ceftobiprole, ceftaroline) among S. aureus strains. Increasing MICs to vancomycin and daptomycin appears to decrease the MICs for anti-MRSA beta-lactams and is referred to as the “see-saw effect.” It is thought that the beta-lactam decreases cell membrane positive charge, thereby enhancing daptomycin binding.
14
Clinical studies examining the combination of beta-lactams with vancomycin or daptomycin have shown improved time to MRSA blood clearance but increased rates of acute kidney injury.15
Appropriate Anti-Staphylococcal Therapy
Empiric S. aureus Bacteremia Therapy
Empiric antibiotic selection in S. aureus bacteremia is critical. Vancomycin monotherapy in MSSA bacteremia is associated with worse clinical outcomes compared with anti-staphylococcal beta-lactams.
16
When susceptibilities of S. aureus bacteremia are not yet known, patients with S. aureus bacteremia should be treated with combined anti-staphylococcal beta-lactam and anti-MRSA agent. De-escalation and appropriate monitoring should be performed once susceptibilities are known.MSSA Bacteremia
Anti-staphylococcal penicillin or cefazolin are preferred and clinically superior to broad-spectrum antibiotics with anti-staphylococcal coverage in MSSA bacteremia. While piperacillin/tazobactam and non-first-generation cephalosporins have activity against MSSA, their use in MSSA bacteremia is associated with higher mortality and worse outcomes.
17
Some exceptions may include febrile neutropenia with mixed infections where broad spectrum anti-staphylococcals may be favored over combination beta-lactam therapy.18
In patients with S. aureus bacteremia who require additional Gram-negative or anaerobic therapy, we recommend discussion with ID to optimize the patient's antimicrobial regimen without sacrificing ideal anti-staphylococcal coverage.We recommend cefazolin as first-line therapy for MSSA bacteremia. Anti-staphylococcal penicillins have similar efficacy to cefazolin but are associated with higher rates of adverse events, including interstitial nephritis.
19
It was traditionally believed that anti-staphylococcal penicillins were superior for penetration of the central nervous system compared with cefazolin, but a growing body of pharmacokinetic studies is reassessing this dogma—and highlighting that cefazolin is a viable option in treating MSSA bacteremia with central nervous system involvement.20
MRSA Bacteremia
Intravenous vancomycin or daptomycin are appropriate for MRSA bacteremia, depending on the clinical scenario. Vancomycin is challenging to dose, as reaching therapeutic levels and steady state depends on a host's volume of distribution and renal function. Traditionally, vancomycin trough concentrations of 15-20 mg/L were thought to achieve sufficient serum vancomycin concentrations to eradicate MRSA. However, contemporary guidelines recommend targeting an area under the curve (AUC) over 24 hours to MIC (AUC/MIC) between 400 and 600 mg/h/L (assuming a vancomycin MIC of 1 mg/L) to minimize vancomycin toxicity.
21
Compared with monitoring vancomycin trough concentrations, AUC-guided therapeutic drug monitoring is labor intensive and requires additional time-critical phlebotomies. Accordingly, some institutions recommend monitoring vancomycin levels to achieve a less restrictive trough concentration of 10-20 mg/L as an alternate strategy to balance drug efficacy against drug toxicity in settings that lack the resources to do AUC-guided monitoring.- Rybak MJ
- Le J
- Lodise TP
- et al.
Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.
Am J Health Syst Pharm. 2020; 77: 835-864
22
The increasingly recognized limitations of vancomycin have prompted usage of daptomycin as an anti-staphylococcal for MRSA bacteremia. Daptomycin is a lipopeptide antibiotic that inserts and disrupts the integrity of the staphylococcal cell wall, leading to rapid depolarization and bacterial cell death. Initial studies demonstrated noninferiority when comparing daptomycin with vancomycin in MRSA bacteremia.
23
Daptomycin is an acceptable agent for MRSA bacteremia and may confer advantages over vancomycin in isolates with an MIC ≥2.Linezolid is an oxazolidinone, a bacteriostatic protein synthesis inhibitor with enhanced in vitro activity in MRSA toxin-producing isolates. While linezolid is reliably utilized for MRSA meningitis, skin and soft tissue infection, and pneumonia, usage in bacteremia has been associated with higher mortality when compared with daptomycin or vancomycin.
24
Thus, daptomycin and vancomycin remain preferred agents in MRSA bacteremia.Monitoring parameters and considerations of anti-staphylococcal agents are summarized in Table 1.
Table 1Anti-Staphylococcal Drugs for Staphylococcus aureus Bacteremia
| Common or Severe Adverse Reactions | Regular Monitoring (weekly) | Considerations | |
|---|---|---|---|
| Cefazolin Cloxacillin, nafcillin, oxacillin | Acute interstitial nephritis Hematologic dyscrasias Rash Hypersensitivity including anaphylaxis† | CBC-diff, Cr | Hypersensitivity cross-reaction of cefazolin with other beta-lactams is rare. Consider its use even in people with documented non-anaphylactic allergy to penicillins or other cephalosporins. Cloxacillin, nafcillin, oxacillin• No renal adjustment needed• Generally requires central line access due to issues with skin irritation and risk of thrombophlebitis when using a peripheral catheter |
| Vancomycin | Nephrotoxicity Neutropenia Thrombocytopenia DRESS | CBC-diff, Cr, pre-vancomycin level | Infusion reaction: resolve by decreasing rate of infusion |
| Daptomycin | Myositis Eosinophilic pneumonia | CBC-diff, Cr, CK | Inhibited by pulmonary surfactant; recommend against usage in pulmonic infections |
| Linezolid | Myelosuppression with ≥2 weeks of use Lactic acidosis Drug interactions | CBC-diff | No renal adjustment needed Excellent pulmonic tissue penetratio Not recommended as first-line therapy in S. aureus bacteremia |
CBC-diff = complete blood count and differential; CK = creatine kinase; Cr = creatinine; DRESS = drug rash with eosinophilia and systemic symptoms.
† More common with anti-staphylococcal penicillins than cefazolin.
‡ Target area under the curve/minimal inhibitory concentration (MIC) of 400-600 mg/h/L (assuming a vancomycin MIC of 1 ug/mL). Alternatively, monitor vancomycin levels to achieve trough concentration of 10-20 mg/L.
§ Suspend statin while on daptomycin therapy.
‖ Risk of serotonin syndrome with concomitant selective serotonin reuptake inhibitors, risk of severe hypertension with concomitant monoamine oxidase inhibitor.
New Developments
Ceftaroline and ceftobiprole are fifth-generation cephalosporins with in vitro activity against MRSA and approved for treatment of skin and soft tissue infection and community-acquired pneumonia.
14
,25
Smaller studies have demonstrated promise in usage for MRSA bacteremia, particularly when clinical failure is observed with intravenous vancomycin or daptomycin. In cases of persistent bacteremia despite appropriate therapy, we recommend ID and Microbiologist consultation if ceftaroline or ceftobiprole usage is being considered due to clinical failure.Discussions on usage of oral anti-staphylococcal agents have become more robust over the last few years. A significant body of literature exists for usage of linezolid in select cases of S. aureus bacteremia given its excellent oral bioavailability.
26
While usage of fluoroquinolone with rifampin was found to have equal efficacy to vancomycin in select cases of right-sided infective endocarditis (IE), its applicability to other cases of S. aureus bacteremia remains questionable. Usage of trimethoprim-sulfamethoxazole, tetracyclines, clindamycin, and oral beta-lactams are not advised owing to a lack of evidence.26
Based on available evidence, we recommend usage of linezolid or fluoroquinolone and rifampin only as salvage therapy when other options are not possible (eg, patients prematurely discharged from hospital with S. aureus bacteremia).Screening Echocardiography and Cardiac Imaging
Echocardiography in patients with S. aureus bacteremia is supported by the European Society of Cardiology and the Infectious Diseases Society of America.
27
,- Habib G
- Lancellotti P
- Antunes MJ
- et al.
2015 ESC Guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).
Eur Heart J. 2015; 36: 3075-3128
28
Upwards of 18% of individuals with S. aureus bacteremia IE do not have clinical stigmata.29
While transesophageal echocardiogram (TEE) has a higher sensitivity compared with TTE for S. aureus infective endocarditis, the specificity of both modalities is equivocal. Usage of TEE over TTE is recommended in patients with prosthetic cardiac valves or intracardiac devices. Patients with complicated S. aureus bacteremia requiring a prolonged (≥6 week) course of anti-staphylococcal therapies need not undergo a TEE so long as a TTE is done to investigate for surgical indications of native IE.7
Other imaging modalities, including cardiac magnetic resonance, cardiac CT, positive emission tomography-computed tomography (PET-CT), and CT angiography can complement echocardiography. Forexample CT angiography can detect abscesses and mycotic aneurysms with diagnostic accuracy similar to that of TEE, in addition to characterizing degree of perivalvular involvement, aortic and coronary vessel anatomy, and aid in preoperative planning.
27
,- Habib G
- Lancellotti P
- Antunes MJ
- et al.
2015 ESC Guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).
Eur Heart J. 2015; 36: 3075-3128
30
While there are no recommendations for end-of-therapy echocardiogram performance, we recommend obtaining one in select cases of IE in which relapse risk is significant. Given common persistence of valvular vegetations, repeat TTE can only be used as a new baseline, which can be compared with future TTEs if suspicion for IE relapse is high enough to warrant further investigation.
Assessment for Metastatic Phenomena and Source Control
Determining source and complications of S. aureus bacteremia informs diagnostic and therapeutic interventions. Directed questioning about recent procedures, trauma, or underlying comorbidities may suggest a source of S. aureus bacteremia. Similarly, the presence of foreign bodies or acute pain syndromes may identify metastatic S. aureus complications.
Management and outcomes differ depending on the source of S. aureus bacteremia. The commonest sources of hospital-acquired and community-acquired S. aureus bacteremia are line-related and skin/soft tissue infections, respectively.
15
Upwards of 40% of individuals with S. aureus bacteremia do not have an apparent source. Pleuropulmonary, osteoarticular, and endovascular sources are also recognized, albeit in lower frequencies.15
,31
The urinary tract is an uncommon source of S. aureus bacteremia and may reflect hematogenous seeding as opposed to urinary infection. One in 5 patients with S. aureus bacteremia and concomitant S. aureus bacteriuria have vertebral osteomyelitis or psoas abscesses and should be closely assessed for same.32
Patients with S. aureus bacteremia require a meticulous physical examination followed by corresponding investigations, as dissemination to osteoarticular, vertebral, and visceral organs is common. For instance, severe headaches should prompt additional investigations for embolic seeding to the brain from endocarditis, and arthropathies should prompt arthrocentesis for assessment of septic arthritis.
Examination for vertebral tenderness should always be conducted, as vertebral discitis can present occultly or may be erroneously attributed to mechanical back pain. Palpation of the vertebrae will elicit point tenderness over the disc involved.
33
Accordingly, an MRI of the spine should be considered even if findings on clinical assessment are subtle. Repeat MRI may be considered in select circumstances of suspected acute discitis, as radiographic findings of vertebral discitis may lag behind symptoms for 10 days.34
PET-CT is an increasingly utilized modality in identifying metastatic complications of S. aureus bacteremia for intervention, particularly when routine investigations, including echocardiogram, are nondiagnostic despite a high pretest probability (eg, confirming vascular graft infection in an individual with unexplained persistent S. aureus bacteremia).
35
However, the expense and need for specialized radiotracers may limit the practicality of PET-CT.White blood cell scans have a role in evaluating embolic phenomenon except for cases with vertebral discitis, as significant uptake of leukocytes within the bone marrow conflicts interpretation.
Achieving source control in patients with S. aureus bacteremia hastens clearance of bacteremia and reduces associated mortality.
36
Endovascular devices, including central lines and intracardiac devices, should be removed in all cases of S. aureus bacteremia, where feasible. Patients with S. aureus bacteremia and prosthetic heart valves or vascular grafts should be investigated for infection. Non-endovascular material, including osteoarticular hardware, typically do not require additional investigations unless directed by clinical examination. Confirmed septic arthritis or epidural abscess require surgical consultation for irrigation and debridement. Similarly, expeditious surgical or radiological drainage are needed in cases with intramuscular or intra-abdominal dissemination. Cardiovascular Surgery consultation is valuable in all cases of S. aureus IE (Table 237
).Table 2Surgical Indications for Staphylococcus aureus Endocarditis
| Indication | Classification of Recommendations |
|---|---|
| Left-sided endocarditis | Strong |
| Endocarditis induced valve dysfunction resulting in heart failure | Strong |
| Endocarditis induced heart block, annular or aortic abscess, or destructive penetrative lesions | Strong |
| Persistent infection (characterized as persistent bacteremia or fever ≥ 5-7 days after initiation of anti-staphylococcal antibiotics) | Strong |
| Relapsing prosthetic valve endocarditis despite an appropriate antimicrobial course | Moderate |
| Recurrent emboli and persistent vegetations despite appropriate antimicrobial therapy | Moderate |
| Vegetations >10 mm in size with clinical evidence of embolic phenomena despite appropriate antimicrobial therapy | Weak |
| Right-sided endocarditis with symptomatic severe valve dysfunction AND evidence of persistent infection | Weak |
37
Duration of Therapy
Repeat BCx are necessary to document bacteria clearance and establish duration of therapy. At minimum, 2 weeks of intravenous anti-staphylococcal therapy from the first negative BCx is needed—and can only be considered when S. aureus bacteremia has met a series of criteria to be considered uncomplicated. Different criteria have been proposed to define the constituents of an uncomplicated S. aureus bacteremia. Based on current literature and our expert opinion, the following should be met to consider S. aureus bacteremia as uncomplicated: 1) clearance of S. aureus bacteremia and corresponding clinical defervescence within the first 48-72 hours of anti-staphylococcal therapy; 2) removable foci of infection; 3) absence of metastatic phenomena; 4) absence of endovascular foreign material (eg, prosthetic valves, cardiac devices, vascular grafts); 5) no evidence of endocarditis on echocardiogram.
38
,39
S. aureus bacteremia is considered complicated when the aforementioned criteria are not met. At minimum, 4 weeks of intravenous anti-staphylococcal therapy from the first negative BCx is needed. Six weeks of therapy is recommended when deep-seated infection, including endocarditis or osteomyelitis, is present (Figure).
Infectious Diseases Consultation
ID specialist consultation is recommended in all cases of S. aureus bacteremia, given its association with improved outcomes.
40
,41
Benefits of ID consultation have a legacy effect, with improved patient outcomes of at least 5 years.42
Reduction of mortality in patients with S. aureus bacteremia was more pronounced with bedside ID consultant compared with telephonic consultations.43
The specific mechanisms in which ID consultation improves outcomes remains unclear; rendering it difficult to characterize the benefit of any unique intervention.Conclusion
The significant prevalence of S. aureus bacteremia coupled with its high mortality rate behooves clinicians to be well versed in managing this bloodstream infection. Although no 2 cases of S. aureus bacteremia are the same, the management of S. aureus bacteremia should involve a series of common evidence-informed clinical considerations. Of all considerations, ID consultation remains quintessential and should be employed for all cases of S. aureus bacteremia, regardless of patient characteristics or clinical presentation.
References
- Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks.Clin Microbiol Rev. 1997; 10: 505-520
- Predictors of mortality in Staphylococcus aureus bacteremia.Clin Microbiol Rev. 2012; 25: 362-386
- Twenty-year trends in outcomes for older adults with acute myocardial infarction in the United States.JAMA Netw Open. 2019; 2e191938
- Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections – United States.MMWR Morb Mortal Wkly Rep. 2019; 68: 214-219
European Centre for Disease Prevention and Control (ECDC). Surveillance atlas of infectious diseases. Available at:https://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&HealthTopic=4. Accessed June 19, 2022.
- Clinical management of Staphylococcus aureus bacteraemia.Lancet Infect Dis. 2011; 11: 208-222
- Forgoing transesophageal echocardiogram in selected patients with complicated Staphylococcus aureus bacteremia.Eur J Clin Microbiol Infect Dis. 2021; 40: 623-631
- Differential expression and roles of Staphylococcus aureus virulence determinants during colonization and disease.mBio. 2015; 6 (e02272-14)
- Pediatric bone and joint infections caused by Panton-Valentine leukocidin-positive Staphylococcus aureus.Pediatr Infect Dis J. 2007; 26: 1042-1048
- Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain.Clin Microbiol Infect. 2008; 14: 384-388
- Time to blood culture positivity in Staphylococcus aureus bacteraemia to determine risk of infective endocarditis.Clin Microbiol Infect. 2021; 27: 1345.e7-1345.e12
Chong YP, Park SJ, Kim HS, et al. Persistent Staphylococcus aureus bacteremia: a prospective analysis of risk factors, outcomes, and microbiologic and genotypic characteristics of isolates. Medicine (Baltimore). 2013;92(2):98-108.
- The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.Clin Infect Dis. 2012; 54: 755-771
- The emerging role of β-lactams in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections.Antimicrob Agents Chemother. 2020; 64 (e00468-20)
- Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Clin Microbiol Rev. 2015; 28: 603-661
- The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.Clin Infect Dis. 2013; 57: 1760-1765
- Comparative effectiveness of exclusive exposure to nafcillin or oxacillin, cefazolin, piperacillin/tazobactam, and fluoroquinolones among a national cohort of veterans with methicillin-susceptible.Open Forum Infect Dis. 2019; 6: ofz270
- The relationship between antibiotic agent and mortality in patients with febrile neutropenia due to Staphylococcal bloodstream infection: a multicenter cohort study.Open Forum Infect Dis. 2022; 9: ofac306
- The safety and economic impact of cefazolin versus nafcillin for the treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections.Infect Dis Ther. 2017; 6: 225-231
- Pharmacokinetic evaluation of cefazolin in the cerebrospinal fluid of critically ill patients.Open Forum Infect Dis. 2022; 9: ofab649
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.Am J Health Syst Pharm. 2020; 77: 835-864
- A Canadian perspective on the revised 2020 ASHP–IDSA–PIDS–SIDP guidelines for vancomycin AUC-based therapeutic drug monitoring for serious MRSA infections.JAMMI. 2021; 6: 3-9
- Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.N Engl J Med. 2006; 355: 653-665
- Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia.Am J Med Sci. 2015; 349: 36-41
- Ceftobiprole for treatment of MRSA blood stream infection: a case series.Infect Drug Resist. 2020; 13: 2667-2672
- A narrative review of early oral stepdown therapy for the treatment of uncomplicated.Open Forum Infect Dis. 2020; 7: ofaa151
- 2015 ESC Guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).Eur Heart J. 2015; 36: 3075-3128
- Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association.Circulation. 2015; 132: 1435-1486
- Staphylococcus aureus bacteremia. Clinical, serologic, and echocardiographic findings in patients with and without endocarditis.Arch Intern Med. 1987; 147: 457-462
- Cardiac computed tomography angiography results in diagnostic and therapeutic change in prosthetic heart valve endocarditis.Int J Cardiovasc Imaging. 2014; 30: 377-387
- Epidemiology and outcome determinants of Staphylococcus aureus bacteremia revisited: a population-based study.Infection. 2019; 47: 961-971
- Incidence and outcomes of Staphylococcus aureus bacteriuria: a population-based study.Clin Infect Dis. 2019; 69: 963-969
- Bacterial spine infections in adults: evaluation and management.J Am Acad Orthop Surg. 2016; 24: 11-18
- The correlation between follow-up MRI findings and laboratory results in pyogenic spondylodiscitis.BMC Musculoskelet Disord. 2020; 21: 428
- Integration of FDG-PET/CT in the diagnostic workup for Staphylococcus aureus bacteremia: a prospective interventional matched-cohort study.Clin Infect Dis. 2021; 73: e3859-e3866
- Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes.Clin Infect Dis. 2020; 70: 566-573
- 2016 The American Association for Thoracic Surgery (AATS) consensus guidelines: surgical treatment of infective endocarditis: executive summary.J Thorac Cardiovasc Surg. 2017; 153: 1241-1258.e29
- Clinical identifiers of complicated Staphylococcus aureus bacteremia.Arch Intern Med. 2003; 163: 2066-2072
- Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study.Antimicrob Agents Chemother. 2013; 57: 1150-1156
- Infectious diseases consultation improves key performance metrics in the management of Staphylococcus aureus bacteremia: a multicentre cohort study.JAMMI. 2019; 4: 24-32
- Impact of infectious diseases consultation on clinical outcomes of patients with Staphylococcus aureus bacteremia in a community health system.Antimicrob Agents Chemother. 2016; 60: 5682-5687
- Association of infectious diseases consultation with long-term postdischarge outcomes among patients with Staphylococcus aureus bacteremia.JAMA Netw Open. 2020; 3e1921048
- Impact of routine bedside infectious disease consultation on clinical management and outcome of Staphylococcus aureus bacteraemia in adults.Clin Microbiol Infect. 2015; 21: 779-785
Article Info
Publication History
Published online: September 27, 2022
Publication stage
In Press Journal Pre-ProofFootnotes
Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Conflicts of Interest: The authors report no conflicts of interests or competing interests related to this manuscript.
Authorship: All authors had access to the data and a role in writing this manuscript.
Identification
Copyright
© 2022 The Authors. Published by Elsevier Inc.
User License
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) | How you can reuse 
Elsevier's open access license policy
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy
00722-7&id=gr1.jpg){kind=link}